Lisocabtagene maraleucel is indicated for adults with certain types of blood cancers, including:

Large B-cell lymphoma (LBCL), such as diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B, who have:
Disease that is refractory to first-line chemoimmunotherapy or relapsed within 12 months of first-line treatment
Disease that is refractory to first-line chemoimmunotherapy or relapsed after first-line treatment and are not eligible for stem cell transplant
Relapsed or refractory disease after two or more lines of systemic therapy
Relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor
Relapsed or refractory follicular lymphoma (FL) after two or more prior lines of systemic therapy
Relapsed or refractory mantle cell lymphoma (MCL) after at least two prior lines of systemic therapy, including a BTK inhibitor

It is used when other treatments have not worked or are no longer effective.